Longeveron (LGVN) EBIT Margin (2020 - 2026)
Longeveron's (LGVN) quarterly EBIT Margin came in at 1199.75% in Q1 2026, up 16009.0% year-on-year from N/an in Q1 2025, and up 18.89% quarter-over-quarter from 1479.18% in Q4 2025.
Longeveron (LGVN) EBIT Margin (2020 - 2026) Analysis & Trends
Longeveron's EBIT Margin history runs 7 years deep, the most recent figure standing at 1199.75% for Q1 2026.
- On a quarterly basis, EBIT Margin rose 16009.0% year-over-year to 1199.75% in Q1 2026; TTM through Mar 2026 was 1881.66%, a 109016.0% decrease from a year earlier, with the FY2025 full-year figure at 1942.2%, down 125148.0% from the prior year.
- EBIT Margin rose to 1199.75% in Q1 2026 per LGVN's latest filing, from 1479.18% in the prior quarter.
- Across five years, EBIT Margin topped out at 601.42% in Q3 2024 and bottomed at 8634.92% in Q4 2023.
- The 5-year median for EBIT Margin is 1479.18% (2025), against an average of 2459.13%.
- Across the five-year window, EBIT Margin surged 792497 bps in 2024 and slumped 473434 bps in 2025, its largest moves.
- Year by year, EBIT Margin stood at 4331.4% in 2022, then plunged by 99 bps to 8634.92% in 2023, then jumped by 92 bps to 709.95% in 2024, then sank by 108 bps to 1479.18% in 2025, then climbed by 19 bps to 1199.75% in 2026.
- Per Business Quant, the three latest LGVN EBIT Margin figures stand at 1199.75% (Q1 2026), 1479.18% (Q4 2025), and 5335.77% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -1,199.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,199.75% |
| Dec 31, 2025 | -1,479.18% |
| Sep 30, 2025 | -5,335.77% |
| Jun 30, 2025 | -1,707.91% |
| Mar 31, 2025 | -1,359.84% |
| Dec 31, 2024 | -709.95% |
| Sep 30, 2024 | -601.42% |
| Jun 30, 2024 | -747.86% |
| Mar 31, 2024 | -746.35% |
| Dec 31, 2023 | -8,634.92% |
| Sep 30, 2023 | -3,440.67% |
| Jun 30, 2023 | -2,632.26% |
| Mar 31, 2023 | -1,690.32% |
| Dec 31, 2022 | -4,331.40% |
| Sep 30, 2022 | -5,187.00% |
| Jun 30, 2022 | -905.79% |
| Mar 31, 2022 | -1,094.84% |
| Dec 31, 2021 | -1,929.19% |
| Sep 30, 2021 | -2,114.22% |
| Jun 30, 2021 | -1,035.17% |